The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global pulmonary arterial hypertension (PAH) drugs market size reached US$ 6.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 9.4 Billion by 2027, exhibiting a growth rate (CAGR) of 5.4% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Pulmonary arterial hypertension (PAH) refers to a life-threatening medical condition characterized by high blood pressure in the arteries that connect the heart to the lungs. It causes the artery walls to tighten and narrow down, thereby exerting additional pressure on the heart to pump blood and weakening the muscles. In adverse cases, it can also compromise the heart’s capacity to pump blood, thus eventually causing heart failure. PAH is characterized by shortness of breath, fatigue and swelling in ankles and legs. It is diagnosed through various tests, such as an echocardiogram, computer tomography (CT) scans, chest X-rays and ventilation-perfusion scans. It is usually treated using various drugs, such as endothelin receptor antagonists (ERAs), vasodilators, calcium channel blockers (CCBs), anticoagulants, diuretics and cardiac glycosides. These drugs can be inhaled, injected or orally administered.
The increasing prevalence of cardiovascular and pulmonary disorders is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population that is more susceptible to such medical ailments is providing a boost to the market growth. In line with this, changes in lifestyles, such as excessive alcohol consumption, a lack of physical activity, and unhealthy dietary patterns, have enhanced the risks of hypertension and high blood pressure. This, along with the development of novel orphan drugs and technologically advanced devices for the treatment of PAH, is favoring the market growth. Other factors, including increasing awareness among the masses regarding the available treatment alternatives for PAH, and improving healthcare infrastructure across the globe, are expected to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global pulmonary arterial hypertension (PAH) drugs market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on drug class, route of administration and end user.
Breakup by Drug Class:
Breakup by Route of Administration:
Breakup by End User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Actelion Pharmaceuticals Ltd (Johnson & Johnson), Arena Pharmaceuticals Inc., AstraZeneca PLC, Bayer Aktiengesellschaft, Daiichi Sankyo Company Limited, Gilead Science Inc., GlaxoSmithKline PLC, Merck KGaA, Novartis International AG, Pfizer Inc. and United Therapeutics Corporation.
|Base Year of the Analysis||2021|
|Segment Coverage||Drug Class, Route of Administration, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Actelion Pharmaceuticals Ltd (Johnson & Johnson), Arena Pharmaceuticals Inc., AstraZeneca PLC, Bayer Aktiengesellschaft, Daiichi Sankyo Company Limited, Gilead Science Inc., GlaxoSmithKline PLC, Merck KGaA, Novartis International AG, Pfizer Inc. and United Therapeutics Corporation|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at